Genomics-Guided Risk Stratification in Myeloma Precursor Conditions: Converging Frameworks From Whole-Genome Sequencing
Technology in Cancer Research & Treatment · 2026-08 · 25
DOI: 10.1177/15330338261503783 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 03.11.2026. Verfasst von Xinyi Xiong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Whole Genome Sequencing, Genomics, Precancerous Conditions. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, Peking Union Medical College Hospital Talent Cultivation Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
Multiple myeloma (MM) remains incurable despite major therapeutic advances, underscoring the unmet need for earlier and genetically informed intervention. The rationale for such intervention lies in the stepwise evolution of MM from precursor states, including monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), during which genetic alterations accumulate and drive the emergence, expansion, and evolution of malignant clones. In 2025, three landmark cohort studies using whole-exome or whole-genome sequencing (WES/WGS) proposed distinct but relevant genomic frameworks for reclassifying disease risk in MGUS and SMM. Despite differences in design and analyses, these frameworks converge on several principles: (i) the malignant genomic architecture of myeloma is established well before clinical progression; (ii) a substantial fraction of clinically defined precursor disease already harbors the hallmarks of overt myeloma; and (iii) WES/WGS-derived features meaningfully improve clinical risk models. In this perspective, we critically reviewed these three contemporaneous frameworks and synthesize their convergent implications, not previously consolidated for clinical use, into a practical approach toward genomics-guided management of myeloma precursor conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Center for Rare Diseases, State Key Laboratory of Complex, Severe, and Rare Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Xinyi Xiong, Xuezhu Wang
Förderung
- CAMS Innovation Fund for Medical Sciences
- Peking Union Medical College Hospital Talent Cultivation Program
- National Natural Science Foundation of China
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Xiong, X., Wang, X., Li, J., & Shen, K. (2026). Genomics-Guided Risk Stratification in Myeloma Precursor Conditions: Converging Frameworks From Whole-Genome Sequencing. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261503783
Vancouver
Xiong X, Wang X, Li J, Shen K. Genomics-Guided Risk Stratification in Myeloma Precursor Conditions: Converging Frameworks From Whole-Genome Sequencing. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261503783
BibTeX
@article{Xiong2026,
author = {Xiong, Xinyi and Wang, Xuezhu and Li, Jian and Shen, Kaini},
title = {Genomics-Guided Risk Stratification in Myeloma Precursor Conditions: Converging Frameworks From Whole-Genome Sequencing},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
volume = {25},
doi = {10.1177/15330338261503783}
}
EUVIMED